+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell-Free DNA Testing Market - Global Forecast 2026-2032- Product Image
Cell-Free DNA Testing Market - Global Forecast 2026-2032- Product Image
Sale

Cell-Free DNA Testing Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6055596
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cell-Free DNA Testing Market is projected to reach USD 7.72 Billion in 2026. It is expected to continue growing at a CAGR of 7.77%, reaching USD 12.15 Billion by 2032.

Cell-Free DNA Testing: Executive Summary

Cell-free DNA (cfDNA) testing analyzes short DNA fragments circulating in bodily fluids, most commonly blood. Clinical applications include prenatal screening, cancer detection and monitoring, transplant assessment, and evaluation of molecular disease characteristics. Its value comes from providing genomic information through minimally invasive sampling, while its limitations include biological variability, interpretation complexity, incidental findings, and the need for confirmatory testing where appropriate.

Clinical Integration Is Reshaping Cell-Free DNA Testing

The field is shifting from specialized laboratory use toward broader integration into clinical pathways. Progress depends on improved assay sensitivity, standardized pre-analytical handling, validation across patient groups, and clearer evidence of clinical utility. Adoption is also influenced by reimbursement, laboratory accreditation, regulatory oversight, clinician education, informed consent, and the ability of health systems to manage results within existing diagnostic workflows.

Artificial Intelligence Strengthens Interpretation, Not Biological Certainty

Artificial intelligence can support cfDNA testing by identifying complex fragment patterns, integrating genomic and clinical variables, prioritizing variants, and improving quality-control processes. These tools may reduce analytical workload and help distinguish clinically relevant signals from background DNA. However, performance remains dependent on representative training data, transparent validation, cybersecurity, and human oversight. AI should complement laboratory and clinical judgment rather than replace confirmatory testing or shared decision-making.

Regional Differences Reflect Infrastructure, Regulation, and Access

North America combines advanced molecular laboratories with established clinical research and regulatory frameworks, while access and reimbursement remain uneven. Europe benefits from strong academic networks and coordinated quality initiatives, although national health-technology assessment and reimbursement pathways differ. Asia-Pacific includes highly developed testing ecosystems alongside settings where infrastructure and specialist capacity are still expanding. Latin America is characterized by growing interest in minimally invasive diagnostics but variable laboratory access and funding. The Middle East is investing in precision-health capabilities, with implementation shaped by national programs and referral structures. Africa presents substantial opportunities for earlier and less invasive diagnosis, alongside persistent constraints involving sample logistics, laboratory capacity, affordability, and data representation.

Cross-Group Insights: Policy Alignment and Health-System Readiness Matter

Within ASEAN, unequal laboratory capacity and cross-border variation make shared standards, workforce development, and referral networks important. BRICS countries span diverse regulatory and health-system conditions, creating opportunities for locally validated assays and stronger genomic data infrastructure. The European Union emphasizes data governance, quality requirements, and cross-border health coordination, but national reimbursement decisions remain consequential. G7 members generally possess strong research and laboratory capabilities, with continuing attention to affordability, evidence, and equitable access. GCC states are building centralized and digitally enabled healthcare systems, supporting coordinated implementation while requiring locally relevant validation. NATO members do not form a single healthcare market, but collaboration in biomedical research, resilience, and secure data practices can support testing capacity.

Country Insights Highlight Varied Adoption Conditions

Australia has strong clinical research and laboratory capabilities, with implementation influenced by geography and public funding. Brazil and Mexico are expanding advanced diagnostics while addressing regional access and laboratory standardization. Canada and the United States have substantial molecular-testing infrastructure, with coverage, regulation, and evidence requirements varying by jurisdiction and payer. China is strengthening domestic precision-medicine capacity, while India is balancing expanding expertise with affordability and uneven access. Japan and South Korea combine sophisticated healthcare systems with aging-population and innovation priorities. France, Germany, Italy, Spain, and the United Kingdom have established research and diagnostic networks, but procurement, assessment, and reimbursement pathways differ across their systems. Russia’s capabilities and access are shaped by domestic infrastructure, regulatory conditions, and international constraints.

Priorities for Leaders: Build Evidence, Reliability, and Trust

Industry leaders should prioritize analytically robust assays with clearly defined intended uses, harmonized specimen handling, and transparent reporting of limitations. Clinical studies should demonstrate patient-relevant utility across diverse populations and care settings, while post-market monitoring should track performance and unintended consequences. Partnerships with laboratories, clinicians, health systems, regulators, and patient groups can improve workflow integration and informed consent. Organizations should also invest in secure data architecture, explainable AI, reimbursement evidence, workforce training, and scalable quality systems rather than pursuing technological complexity without clinical relevance.

Research Methodology: Evidence-Led Market Interpretation

This executive summary uses the supplied market definition-cell-free DNA testing-as the analytical scope. The assessment is structured around established application areas, technology characteristics, clinical workflow requirements, regulatory considerations, health-system factors, and geographic variation. Insights are synthesized qualitatively from verified, publicly documented principles relevant to cfDNA testing, including assay validation, laboratory quality, clinical utility, data governance, and access conditions. No market estimates, market shares, forecasts, or company-specific claims are included.

Conclusion: Sustainable Value Depends on Clinical Utility

Cell-free DNA testing is becoming an important component of minimally invasive molecular diagnostics, but durable adoption depends on more than assay innovation. Reliable pre-analytics, validated interpretation, equitable access, responsible AI, appropriate confirmation, and integration into clinical decision-making will determine its practical value. Leaders that connect technical performance with evidence, governance, affordability, and patient-centered care will be best positioned to support safe and meaningful use across diverse healthcare environments.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cell-Free DNA Testing Market, by Offerings
7.1. Introduction
7.2. Infectious Diseases Testing
7.3. Oncology & Cancer Management
7.3.1. Early Detection and Screening
7.3.2. Minimal Residual Disease (MRD) Assessment
7.4. Prenatal Screening
7.4.1. Non-Invasive Prenatal Testing
7.4.2. Preimplantation Genetic Testing
7.5. Transplantation Testing
8. Cell-Free DNA Testing Market, by Technology Platform
8.1. Introduction
8.2. Mass Spectrometry
8.3. Microfluidics
8.4. Nucleic Acid Technology
8.5. Polymerase chain reaction (PCR)
8.6. Single-molecule Methylation
9. Cell-Free DNA Testing Market, by End-User
9.1. Introduction
9.2. Diagnostic Laboratories & Testing Centers
9.3. Hospitals & Clinics
10. Cell-Free DNA Testing Market, by Region
10.1. Introduction
10.2. Asia-Pacific
10.3. North America
10.4. Latin America
10.5. Europe
10.6. Middle East
10.7. Africa
11. Cell-Free DNA Testing Market, by Group
11.1. Introduction
11.2. ASEAN
11.3. GCC
11.4. European Union
11.5. BRICS
11.6. G7
11.7. NATO
12. Cell-Free DNA Testing Market, by Country
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. United Kingdom
12.7. Germany
12.8. France
12.9. Russia
12.10. Italy
12.11. Spain
12.12. China
12.13. India
12.14. Japan
12.15. Australia
12.16. South Korea
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. Market Concentration Analysis, 2025
13.2.1. Concentration Ratio (CR)
13.2.2. Herfindahl Hirschman Index (HHI)
13.3. Recent Developments & Impact Analysis, 2025
13.4. Product Portfolio Analysis, 2025
13.5. Benchmarking Analysis, 2025
14. Company Profiles
14.1. Abbott Laboratories
14.2. Adaptive Biotechnologies Corporation
14.3. Agilent Technologies, Inc.
14.4. BGI Genomics Co., Ltd.
14.5. Biodesix, Inc.
14.6. Bio-Rad Laboratories, Inc.
14.7. F. Hoffmann-La Roche
14.8. Fulgent Genetics, Inc.
14.9. Guardant Health, Inc.
14.10. Laboratory Corporation of America Holdings
14.11. llumina, Inc.
14.12. Myriad Genetics, Inc.
14.13. Natera, Inc.
14.14. OPKO Health, Inc.
14.15. PerkinElmer, Inc.
14.16. Qiagen N.V.
14.17. Revvity, Inc
14.18. SOPHiA GENETICS AG
14.19. Stilla Technologies
14.20. Thermo Fisher Scientific, Inc.
15. Key Experts
LIST OF FIGURES
FIGURE 1. Global Cell-Free DNA Testing Market, Years Considered for the Study
FIGURE 2. Global Cell-Free DNA Testing Market, Research Design
FIGURE 3. Global Cell-Free DNA Testing Market, Research Framework
FIGURE 4. Global Cell-Free DNA Testing Market, Data Triangulation
FIGURE 5. Global Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Cell-Free DNA Testing Market Size, by Offerings, 2025 vs 2032 (%)
FIGURE 7. Global Cell-Free DNA Testing Market Size, by Offerings, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Cell-Free DNA Testing Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 9. Global Cell-Free DNA Testing Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Cell-Free DNA Testing Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 11. Global Cell-Free DNA Testing Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Cell-Free DNA Testing Market Size, by Region, 2025 vs 2032 (%)
FIGURE 13. Global Cell-Free DNA Testing Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Cell-Free DNA Testing Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 15. Global Cell-Free DNA Testing Market Size, by Country, 2025 vs 2032 (%)
FIGURE 16. Global Cell-Free DNA Testing Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Cell-Free DNA Testing Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Cell-Free DNA Testing Market Segmentation & Coverage
TABLE 2. Global Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 3. Global Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 4. Global Infectious Diseases Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Infectious Diseases Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Infectious Diseases Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Oncology & Cancer Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Oncology & Cancer Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Oncology & Cancer Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Early Detection and Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Early Detection and Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Early Detection and Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Minimal Residual Disease (MRD) Assessment Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Minimal Residual Disease (MRD) Assessment Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Minimal Residual Disease (MRD) Assessment Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Prenatal Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Prenatal Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Prenatal Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Non-Invasive Prenatal Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Non-Invasive Prenatal Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Non-Invasive Prenatal Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Preimplantation Genetic Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Preimplantation Genetic Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Preimplantation Genetic Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Transplantation Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Transplantation Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Transplantation Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 29. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Microfluidics Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Microfluidics Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Microfluidics Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Nucleic Acid Technology Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Nucleic Acid Technology Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Nucleic Acid Technology Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Polymerase chain reaction (PCR) Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Polymerase chain reaction (PCR) Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Polymerase chain reaction (PCR) Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Single-molecule Methylation Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Single-molecule Methylation Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Single-molecule Methylation Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 45. Global Diagnostic Laboratories & Testing Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Diagnostic Laboratories & Testing Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Diagnostic Laboratories & Testing Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 58. North America Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. North America Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 60. North America Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 61. North America Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 62. North America Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 63. North America Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 64. Latin America Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Latin America Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 66. Latin America Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 67. Latin America Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 68. Latin America Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 69. Latin America Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 70. Europe Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Europe Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 72. Europe Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 73. Europe Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 74. Europe Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 75. Europe Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 76. Middle East Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Middle East Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 78. Middle East Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 79. Middle East Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 80. Middle East Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 81. Middle East Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 82. Africa Cell-Free DNA Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Africa Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 84. Africa Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 85. Africa Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 86. Africa Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 87. Africa Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 88. Global Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. ASEAN Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. ASEAN Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 91. ASEAN Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 92. ASEAN Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 93. ASEAN Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 94. ASEAN Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 95. GCC Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. GCC Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 97. GCC Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 98. GCC Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 99. GCC Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 100. GCC Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 101. European Union Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. European Union Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 103. European Union Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 104. European Union Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 105. European Union Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 106. European Union Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 107. BRICS Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. BRICS Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 109. BRICS Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 110. BRICS Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 111. BRICS Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 112. BRICS Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 113. G7 Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. G7 Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 115. G7 Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 116. G7 Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 117. G7 Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 118. G7 Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 119. NATO Cell-Free DNA Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. NATO Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 121. NATO Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 122. NATO Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 123. NATO Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 124. NATO Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 125. Global Cell-Free DNA Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. United States Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 127. United States Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 128. United States Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 129. United States Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 130. United States Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 131. United States Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 132. Canada Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 133. Canada Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 134. Canada Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 135. Canada Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 136. Canada Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 137. Canada Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 138. Mexico Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 139. Mexico Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 140. Mexico Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 141. Mexico Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 142. Mexico Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 143. Mexico Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 144. Brazil Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 145. Brazil Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 146. Brazil Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 147. Brazil Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 148. Brazil Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 149. Brazil Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 150. United Kingdom Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 151. United Kingdom Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 152. United Kingdom Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 153. United Kingdom Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 154. United Kingdom Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 155. United Kingdom Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 156. Germany Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 157. Germany Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 158. Germany Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 159. Germany Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 160. Germany Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 161. Germany Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 162. France Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 163. France Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 164. France Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 165. France Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 166. France Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 167. France Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 168. Russia Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 169. Russia Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 170. Russia Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 171. Russia Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 172. Russia Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 173. Russia Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 174. Italy Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 175. Italy Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 176. Italy Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 177. Italy Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 178. Italy Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 179. Italy Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 180. Spain Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 181. Spain Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 182. Spain Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 183. Spain Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 184. Spain Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 185. Spain Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 186. China Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 187. China Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 188. China Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 189. China Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 190. China Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 191. China Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 192. India Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 193. India Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 194. India Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 195. India Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 196. India Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 197. India Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 198. Japan Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 199. Japan Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 200. Japan Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 201. Japan Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 202. Japan Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 203. Japan Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 204. Australia Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 205. Australia Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 206. Australia Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 207. Australia Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 208. Australia Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 209. Australia Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 210. South Korea Cell-Free DNA Testing Market Size, 2017-2032 (USD Million)
TABLE 211. South Korea Cell-Free DNA Testing Market Size, by Offerings, 2017-2032 (USD Million)
TABLE 212. South Korea Cell-Free DNA Testing Market Size, by Oncology & Cancer Management, 2017-2032 (USD Million)
TABLE 213. South Korea Cell-Free DNA Testing Market Size, by Prenatal Screening, 2017-2032 (USD Million)
TABLE 214. South Korea Cell-Free DNA Testing Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 215. South Korea Cell-Free DNA Testing Market Size, by End-User, 2017-2032 (USD Million)
TABLE 216. Global Cell-Free DNA Testing Market Share, by Key Player, 2025
TABLE 217. Global Cell-Free DNA Testing Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Biodesix, Inc.
  • Bio‐Rad Laboratories, Inc.
  • F. Hoffmann‐La Roche
  • Fulgent Genetics, Inc.
  • Guardant Health, Inc.
  • Laboratory Corporation of America Holdings
  • llumina, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OPKO Health, Inc.
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Revvity, Inc
  • SOPHiA GENETICS AG
  • Stilla Technologies
  • Thermo Fisher Scientific, Inc.

Related Topics

Related Reports

Cell-free DNA Mutation Diagnostics Market - Global Forecast 2026-2032 - Product Image

Cell-free DNA Mutation Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Cell-Free DNA Collection Tube Market - Global Forecast 2026-2032 - Product Image

Cell-Free DNA Collection Tube Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Cell Free DNA (cfDNA) Testing Market Report 2026 - Product Image

Cell Free DNA (cfDNA) Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Cell-Free DNA Kit Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Cell-Free DNA Kit Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cell-Free DNA Isolation and Extraction Market Report 2026 - Product Image

Cell-Free DNA Isolation and Extraction Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Cell Free DNA Market

The Cell Free DNA (cfDNA) market is a subset of the genomics industry that focuses on the analysis of circulating DNA fragments in the bloodstream. It is used to detect genetic abnormalities, such as chromosomal aneuploidy, and to monitor cancer progression. cfDNA testing is also used to detect fetal genetic abnormalities during pregnancy. The cfDNA market is expected to grow rapidly in the coming years, driven by increasing demand for non-invasive prenatal testing and the development of new technologies. The market is also expected to benefit from the increasing availability of cfDNA testing kits and the growing awareness of its potential applications. Notable companies in the cfDNA market include Illumina, Thermo Fisher Scientific, Qiagen, Natera, and Guardant Health. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.